

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**China Animal Healthcare Ltd.**

中國動物保健品有限公司\*

(Incorporated in Bermuda with limited liability)

(Hong Kong Stock code: 0940)

### **BUSINESS UPDATE**

This announcement is made by China Animal Healthcare Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.24A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

### **BUSINESS UPDATE**

Reference is made to the announcements of the Company dated 30 November 2015, 1 February 2016 and 17 May 2016 in relation to, among other things, disclosed the details of recent progress on the operation and business development of the Company.

Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as defined in the above announcements.

The Company would like to inform its Shareholders that, notwithstanding trading in the shares of the Company on the Stock Exchange is suspended, the business of the Group has been operating normally and is sustainable.

The Group continues to carry on its principal business of sale of Biological Drugs and its priority is still on product quality and biosafety work. To lay the foundation for the sustainable development of the Group, the Group has been focused on the following:

1. To complete reconstruction of the quality inspection room of the GMP certified production plant and expansion of animal inspection room and laboratory according to the notices, "Foot-and-Mouth Disease, Highly Pathogenic Avian Influenza Vaccine Production Enterprise Planning" and "Three-Level Protection Standard for Biosafety of Veterinary Vaccine Production Enterprises" that were issued by the Ministry of Agriculture;

2. Management of production and operation standards: Based on full implementation of existing GMP, verify compliance of operational policies and procedures and ensure all quality standards are met; and
3. To continue to meet the market's expectation on the quality of product: The enhancement of the technical process and optimization of the production process are achieved by focusing on improvement of the antigen content which will result in improvement of the product quality.

The Company will keep its shareholders and potential investors informed of any material development in connection with the above matters, including but not limited to any material change to the resumption progress as and when appropriate with the Listing Rules.

### **CONTINUAL SUSPENSION OF TRADING**

At the request of the Company, the shares of the Company have been suspended from trading on the Stock Exchange from 9 a.m. on 30 March 2015. Trading in the Company's shares will continue to suspend until further notice.

**Shareholders and potential investors are advised to exercise caution when dealing in the Shares.**

By order of the Board  
**China Animal Healthcare Ltd.**  
**Wang Yongwei**  
*Chairman, Executive Director*

Hong Kong, 15 February 2019

*As at the date of announcement, the executive Director is Mr. Wang Yongwei.*

*\* For identification purpose only*